CytoReason, an Israeli company developing computational disease models for more efficient drug discovery and development, announced on Wednesday a collaboration with German multinational science and technology company, Merck, to profile one of its leading immuno-oncology drugs.
Follow Israel Hayom on Facebook and Twitter
Multiple drugs created to cure the same disease have varying effects on certain patient populations depending on the drug's mechanism of action (MoA) and on patients' characteristics. CytoReason will use its machine learning platform and proprietary computational disease models to verify Merck's therapeutic hypothesis, providing a deeper analysis of the drug's MoA.
The company will analyze data from hundreds of patients from phase 1 and 2 studies to identify relevant patient populations, as well as prioritize tumor types for which the drug may be most effective against.
"We are thrilled to be working with the talented team at Merck," said David Harel, co-founder and CEO of CytoReason. "Merck's rich medical database and expertise in immuno-oncology will enable us to help create more accurate models of the disease with CytoReason's advanced AI technology. This collaboration might help identify which type of tumor the drug will be most effective for, and has the potential to save the lives of millions who suffer from cancer."
